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Abstract
Background: False negative and indeterminate Interferon Gamma Release Assay (IGRA) results are a well
documented problem. Cigarette smoking is known to increase the risk of tuberculosis (TB) and to impair
Interferon-gamma (IFN-γ) responses to antigenic challenge, but the impact of smoking on IGRA performance is not
known. The aim of this study was to evaluate the effect of smoking on IGRA performance in TB patients in a low
and high TB prevalence setting respectively.
Methods: Patients with confirmed TB from Denmark (DK, n = 34; 20 smokers) and Tanzania (TZ, n = 172;
23 smokers) were tested with the QuantiFERON-TB Gold In tube (QFT). Median IFN-γ level in smokers and non
smokers were compared and smoking was analysed as a risk factor for false negative and indeterminate QFT results.
Results: Smokers from both DK and TZ had lower IFN-γ antigen responses (median 0.9 vs. 4.2 IU/ml, p = 0.04
and 0.4 vs. 1.6, p < 0.01), less positive (50 vs. 86%, p = 0.03 and 48 vs. 75%, p < 0.01) and more false negative
(45 vs. 0%, p < 0.01 and 26 vs. 11%, p = 0.04) QFT results. In Tanzanian patients, logistic regression analysis adjusted
for sex, age, HIV and alcohol consumption showed an association of smoking with false negative (OR 17.1,
CI: 3.0-99.1, p < 0.01) and indeterminate QFT results (OR 5.1, CI: 1.2-21.3, p = 0.02).
Conclusions: Cigarette smoking was associated with false negative and indeterminate IGRA results in both a high
and a low TB endemic setting independent of HIV status.
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Background
Diagnosis of latent tuberculosis (TB) infection continues to
constitute a major problem for control of the TB epidemic.
Although Interferon Gamma Release Assays (IGRAs) are
more specific than the tuberculin skin test (TST), espe-
cially in BCG vaccinated individuals, IGRAs still suffer
from suboptimal sensitivity [1-3]. A meta-analysis pub-
lished in 2011 pooled results from 23 studies of the most
widely used IGRA, the QuantiFERON-TB Gold In tube
test (QFT) and found that an average of 20% of patients
with active TB have a false negative or indeterminate QFT
result [3].
Several explanations for the relative high rate of false
negative results have been proposed, the most rational
and well-documented being immuno-suppression as
seen in advanced HIV infection and during treatment
with immunosuppressive drugs [4-6]. In addition age < 5
years [7-9] and factors such as end stage renal disease
[10] old age (>70 years) [11,12] and others have been
proposed [1,7,13].
It is well documented, that smoking is an independent
predictor of TB infection, progression of latent infection
to active TB disease and death from TB [14,15]. A re-
cently published study found that mice infected with M.
tuberculosis (M.tb.) and later exposed to tobacco smoke
had reduced Interferon-gamma (IFN-γ) responses fol-
lowing T-cell stimulation [16]. This is in accordance
with other recent studies in humans showing that expos-
ure to tobacco smoke reduces IFN-γ production in
* Correspondence: peravn@gmail.com
1Clinical Research Centre, Copenhagen University Hospital Hvidovre,
Kettegårds Alle 30, 2650, Hvidovre, Denmark
2Department of Pulmonary and Infectious Diseases, Copenhagen University
Hospital Hillerød, Dyrehavevej 29, Hillerød 3400, Denmark
Full list of author information is available at the end of the article
© 2012 Aabye et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Aabye et al. BMC Infectious Diseases 2012, 12:379
http://www.biomedcentral.com/1471-2334/12/379
epithelial cells after antigenic challenge [17] and impairs
IFN-γ mediated signaling [18-20] and vaccine efficacy
[21,22]. These findings suggest a negative effect of smok-
ing on the immune defense which in theory might affect
the performance of immunodiagnostic tests, such as the
IGRAs.
We hypothesized that smoking impairs IGRA per-
formance. Thus, in this study we evaluate the effect of
smoking on IFN-γ responsiveness, and the association of
smoking with indeterminate and/or false negative QFT
results in a cohort of Tanzanian patients and in a small
Danish cohort.
Methods
Setting and participants
Denmark
Patients from three university hospitals in the Copenhagen
Region diagnosed with confirmed (culture or Nucleic Acid
Amplification Test) TB in 2009/2010 and having had a
QFT test done up to 30 days before the TB diagnosis were
identified using the national Danish TB Register. Informa-
tion on patient characteristics, including smoking status,
and QFT results were obtained from patient records. Ex-
clusion criteria were: >1 week of anti-TB therapy and
missing QFT or smoking status. Smokers were defined as
current smokers at the time of QFT testing. Alcohol con-
sumers were defined as those with a daily consumption
of alcohol.
Tanzania
In 2006, 300 newly diagnosed pulmonary TB patients were
recruited prospectively through the National Tuberculosis
and Leprosy Program in Mwanza. Inclusion criteria were:
available QFT and HIV results, available smoking history
and a positive culture for M. tb. Exclusion criteria were:
patients <15 years, pregnancy and other serious co-mor-
bidity. Information on demographics, smoking habits and
alcohol consumption were obtained by interview. Ques-
tions on smoking and alcohol habits were recorded as a
simple yes/no answer. A detailed description of patient en-
rolment, TB diagnosis, HIV and QFT testing and sample
handling is available in [13]. Sensitivity analysis of the QFT
has been previously published on this material [13,23].
Laboratory tests
Denmark
All QFT tests were done as part of the diagnostic work-
up. At the hospital laboratory, QFT tubes were incu-
bated, centrifuged and refrigerated. Within one day they
were transported to the Staten Serum Institute where
QFT ELISAs (Cellestis, Qiagen, Düsseldorf, Germany)
were performed and results interpreted according to
manufacturer’s instruction.
Tanzania
The QFT tests were taken as part of a research project
[13,23]. Following stimulation, QFT plasma supernatants
were frozen at −80°C and shipped to Denmark on dry
ice. At Hvidovre Hospital plasma samples were thawn,
QFT ELISAs were performed and results interpreted in
accordance with manufacturer’s instructions.
The QFT test includes blood sample tubes coated with
saline (nil), phytohaemagglutinin (PHA; mitogen) and
peptides from the proteins ESAT-6, CFP-10 and TB7.7
(TB antigens) respectively. Nil levels were subtracted from
IFN-γ levels in the antigen and mitogen tubes respectively.
Crude IFN-γ levels were not corrected for nil levels. IFN-γ
responses >10 IU/ml overshoot the upper limit of the
QFT assay and were therefore set to 10 IU/ml in accord-
ance with manufacturer’s guidelines.
Statistical analysis
Data were analysed using SAS 9.2 (SAS Institute, Cary,
North Carolina, USA). Paired proportions were com-
pared using Chi-square or Fisher’s exact tests. Age was
analysed using Wilcoxon signed-rank test. Logistic re-
gression was used to determine odds ratios (ORs) and
using the Haldane correction if cells contained zero. A
model adjusted for sex, age, HIV infection and alcohol
consumption was used to determine ORs, but only in
Tanzanian patients due to the few patients in the Danish
group. All tests were two-sided, results with a p-value
≤0.05 were considered significant.
Ethical considerations
Ethical permission was obtained from the ethics commit-
tee of the National Institute for Medical Research (NIMR)
in Tanzania. Study approval was given by The Danish
Central Medical Ethics Committee. Written informed
consent was obtained from all Tanzanian patients enrolled
in the study. Data from Danish patients were drawn from
register based data and collected in agreement and accord-
ance with the terms of the Danish Data Protection
Agency. Written consent was not required and therefore
not obtained.
Results
Danish patients
A total of 52 patients were identified with positive cul-
ture and/or PCR for TB. Eighteen patients were
excluded due to lack of information on smoking status
(n = 13), >1 month between QFT result and TB diagno-
sis (n = 2) and age below 15 years (n = 3) respectively
leaving 34 patients available for final analysis; 4 (8%)
were HIV-positive. Twenty (59%) were current smokers.
More smokers than non-smokers consumed alcohol (p
= 0.03), but there was no difference in age (p = 0.15), sex
(p = 0.10) and HIV-status (p = 0.63) (Table 1). Patients
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were primarily from Greenland (n = 8), Denmark (n = 7),
Pakistan (n = 5), East Africa (n = 5) and Southeast Asia
(n = 5). Most patients had pulmonary TB (n = 23), 8 had
extrapulmonary TB (of these 4 in lymph nodes, 2 men-
ingitis, 1 peritoneal and 1 in bone), 2 had miliary and 1
pleural TB.
Tanzanian patients
A total of 172 patients with active culture confirmed pul-
monary TB and a QFT test were included for analysis; 75
(44%) were HIV-positive (Table 1). Twenty-three (13%)
were current smokers and all were cigarette smokers.
More smokers were male and alcohol consumers, but
fewer were HIV-infected. No difference was found in age.
Effect of smoking on crude IFN-γ levels and QFT test
performance and association with risk factors in Danish
patients
Smokers had lower levels of antigen dependent IFN-γ
(median 0.9 vs. 4.2 IU/ml, p = 0.04). Levels of mitogen
induced IFN-γ were similar (median 9.6 vs. >10.0 IU/ml,
p = 0.98). No significant differences were found in nil
IFN-γ levels (median 0.19 vs. 0.18 IU/ml, p = 0.20)
(Figure 1A).
Smokers had fewer positive QFT results 50% (10/20)
compared to non smokers 86% (12/14) (p = 0.03) and
smokers had more false negative 45% (9/20) compared to
non smokers 0% (0/14) (p = 0.004), while no difference was
seen for the proportion of indeterminate results (Table 2).
By univariate analysis comparing false negative and in-
determinate results respectively to positive results,
smoking was associated with a false negative (OR 11.3,
95% CI: 1.2-287.7, p = 0.02), but not with an indetermin-
ate QFT result (OR 0.6, 95% CI: 0.05-7.6, p = 0.69). All
(9/9) patients with false negative results were either
smokers or HIV-infected. Logistic regression analysis
was not performed in Danish patients due to low n and
lack of power.
Effect of smoking on crude IFN-γ levels and QFT test
performance and association with risk factors in
Tanzanian patients
Smokers had lower levels of antigen dependent IFN-γ
(median 0.39 vs. 1.60 UI/ml, p < 0.01). There was no sig-
nificant reduction in levels of mitogen induced IFN-γ in
smokers (median 0.83 vs. 1.21 IU/ml, p = 0.16). No sig-
nificant differences were found in nil levels (Figure 1B).
Smokers had fewer positive QFT results 48% (11/22)
compared to non-smokers 75% (112/150) (p = 0.01) and
more a false negative QFT 26% (6/22) versus 16% (11/150)
(p = 0.04) (Table 2). No significant difference was found in
the proportion of indeterminate results.
Table 1 Background characteristics of Danish and Tanzanian TB patients
Danish patients (n = 34) Tanzanian patients (n = 172)
Non-smokers (n = 14) Smokers (n = 20) p Non-smokers (n = 149) Smokers (n = 23) p
Male sex, n (%) 8 (57) 16 (80) 0.15 89 (60) 20 (87) 0.01
Age, median (range) 29 (24–76) 50 (23–62) 0.10 32 (15–84) 32 (22–69) 0.50
Alcohol, n (%)* 0 (0) 7 (35) 0.03 27(18) 16 (70) <0.001
HIV, n (%) 1 (7) 3 (15) 0.63 71 (48) 4 (17) 0.01
Demographic characteristics of Danish and Tanzanian study participants. P-values are for comparison between non-smokers and smokers (Wilcoxon signed rank
test and chi-square test). *For Danish patients, alcohol is defined as daily consumption. For Tanzanian patients, alcohol is defined as simply reporting to
consuming alcohol at any level.
Figure 1 Influence of smoking on crude IFN-γ responses in Danish and Tanzanian TB patients. In non-smokers (NS) and smokers (S), levels
of Interferon-γ were measured in supernatants from QuantiFERON-TB Gold In tube blood collection tubes after incubation with saline (Nil), M.
tuberculosis-specific antigens (Antigen) or phytohaemagglutinin (Mitogen). Nil levels of antigen and mitogen values have NOT been subtracted.
Medians and p-values for comparison of nil, antigen and mitogen levels between non-smokers (14 Danish patients and 149 Tanzanian patients)
and smokers (20 Danish patients and 23 Tanzanian patients) are shown (Wilcoxon signed rank test).
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By univariate analysis comparing false negative and in-
determinate results respectively to positive results,
smoking was associated with a false negative (OR 3.8,
95% CI: 1.2-11.8, p = 0.02), but not with an indetermin-
ate QFT result (OR 2.9, 95% CI: 0.97-8.7, p = 0.06)
(Table 3).
Logistic regression analysis adjusted for sex, age, HIV in-
fection and alcohol consumption (Table 4) showed an as-
sociation between smoking and false negative results (OR:
17.14 (95%CI: 2.96-99.11, p = 0.0015) and indeterminate
results (OR: 5.13 (1.24-21.25, p = 0.02). There was an asso-
ciation between HIV and indeterminate results (OR: 4.34
1.59-11.85, p = 0.0041), but not false negative results (OR:
2.11 (0.73-6.14, p = 0.17). We found an inverse association
with alcohol consumption and false negative results (OR:
0.12(0.02-0.77))(p = 0.03), but not with indeterminate
results (0.60, (0.18-1.97)) (p = 0.40).
Patients who had smoked for more than five years had
more false negative or indeterminate results than patients
who had smoked for less than five years, but the difference
was not statistically significant (58 vs. 25%, p = 0.57) (data
not shown).
Discussion
This is, to our knowledge, the first publication showing
that IGRA performance is negatively affected by smok-
ing. We have shown that QFT performance is impaired
in TB patients that are cigarette smokers in both a high
and a low TB prevalence setting. Smokers had lower
crude IFN-γ responses to the TB specific antigens and
smoking was associated with both false negative and in-
determinate results QFT results. Since the introduction
of IGRA, we and others, have been able to identify sev-
eral risk factors associated with impaired performance
where the IGRA results should be interpreted with cau-
tion [4,13]. The present study adds further information
to this knowledge and should help us to interpret inde-
terminate results, explain false negative results, and in
the end led to rational clinical use of the IGRAs.
Our results are in line with several previous publica-
tions showing that T cell function is greatly reduced in
smokers [16-20,24,25]. This immunological impairment
in smokers has been shown to be of notable clinical im-
portance, e.g. by increasing incidence, morbidity and
mortality of infectious diseases [26] as well as impairing
vaccine efficacy, even in children exposed to second
hand smoking [21,22].
Our findings suggest that in both high and low resource
settings, caution might be necessary when interpreting
IGRA results in smokers, especially since smoking was
strongly associated with false negative and not just inde-
terminate results. Although becoming less common in
most high resource settings where implementation of
IGRAs is at present considered most realistic, smoking is
still prevalent in many high resource countries, especially
among the sub populations that also have the highest risk
of TB infection. Furthermore, smoking is becoming in-
creasingly common in low resource TB/HIV endemic
areas [14]. Smoking increases morbidity and mortality
from TB disease [14,15,27-29], suggesting that the increas-
ing smoking prevalence in high burden regions could add
to the effects of HIV in fuelling the TB epidemic. Further
adding to this possibly devastating effect of smoking, the
prospect of a potential benefit from using IGRAs as part
of the TB control strategy in low resource settings seem, if
possible, even more bleak.
Smoking was associated with more indeterminate QFT
results in the Tanzanian patients in our study also when
Table 2 Distribution of QuantiFERON-TB Gold In tube test results in non-smokers and smokers respectively in Danish
and Tanzanian TB patients
Danish patients (n = 34) Tanzanian patients (n = 172)
Non-smokers (n = 14) Smokers (n = 20) p Non-smokers (n = 150) Smokers (n = 22) p
Positive, n (%) 12 (86) 10 (50) 0.03 112 (75) 11 (48) 0.01
Negative, n (%) 0 (0) 9 (45) 0.004 16 (11) 6 (26) 0.04
Indeterminate, n (%) 2 (14) 1 (5) 0.56 21 (14) 6 (26) 0.14
Distribution of QFT and IP-10 results for non-smokers and smokers respectively compared by chi square test. Each outcome was tested against the pooled
proportion of the other possible outcomes. QFT: QuantiFERON-TB Gold In tube test.
Table 3 Odds ratios for the association between smoking and false negative or indeterminate result in an univariate
analysis for 34 Danish and 172 Tanzanian TB patients
False negative QFT Indeterminate QFT
OR (95% CI) p OR (95% CI) p
Danish TB pt 11.3, 95% CI: 1.2-287.7 p = 0.02 0.6, 95% CI: 0.05-7.6 p = 0.69
Tanzanian 3.8, 95% CI: 1.2-11.8 p = 0.02 2.9, 95% CI: 0.97-8.7 p = 0.06
Odds ratios (OR) were for false negative results and indeterminate results in univariate analysis in 34 Danish and 172 Tanzanian patients.
Possible predictors for a false negative and indeterminate QFT result respectively were identified by univariate analysis in 34 Danish and 172 Tanzanian patients
with bacteriologically confirmed pulmonary TB (Table 3).
Aabye et al. BMC Infectious Diseases 2012, 12:379 Page 4 of 6
http://www.biomedcentral.com/1471-2334/12/379
adjusting for HIV infection. This is in line with previous
studies showing that IFN-γ responses to mitogen stimu-
lation are impaired in smokers compared to non-
smokers [16-20,24,25]. We were therefore surprised to
find that smokers did not have lower median IFN-γ
responses to the mitogen in the present study. The lack
of a difference in mitogen responses between smokers
and non-smokers might be explained by a lack of power
or by the fact that the mitogen responses frequently
overshot the upper limit of the QFT assay making quan-
tification of responses in the high range impossible. An-
other explanation is that smokers have a higher white
blood cell count and previous studies have suggested
that this is a compensatory mechanism for T cell anergy
[24]; A higher white blood cell count might thus recu-
perate at least some of the IFN-γ response to mitogens.
We found that more smokers consumed alcohol, but
this seemed to have a protective effect against having a
false negative QFT result. Alcohol consumption has pre-
viously been identified as a protective factor for all-cause
mortality in epidemiological studies and the effects is
believed to be driven by the fact that patients who are
very sick might be less inclined to drink alcohol [30].
However, severely ill patients might be more likely to
have an indeterminate or false negative QFT result [31].
Thus the apparent protective effect of alcohol consump-
tion remains unanswered.
Limitations
We used active TB infection as a golden standard for in-
fection with M.tb and as a proxy for LTBI in order to de-
termine the effect of smoking on antigen specific
responses. IGRA are not recommended for diagnosing
active TB, and using active TB as proxy for LTBI is con-
troversial, but necessary in hypothesis generating studies
as the present.
The immune response in patients with active TB may be
compromised due to ongoing infection and the conse-
quence may be biased results if. i.e. smokers with active
TB were more severely ill compared to non-smokers.
Using active TB as a surrogate for LTBI is still the only
way to screen potential of risk factors influencing IGRA
test performance and similar approach has been used to
evaluate the performance of IGRAs in HIV co-infected TB
patients. A strategy that resulted in recommendations
against the use of IGRAs in patients with compromised
immune function [32].
Our results cannot be directly applied to healthy per-
sons with LTBI, and studies in healthy individuals are
needed to confirm our results.
The numbers of smokers in the studies were relatively
small and because of missing data we did not have suffi-
cient power to determine the impact of the number of
cigarettes smoked. Also due to low sample size, the logistic
regression model could not be expanded to the Danish co-
hort and to include other possible predictors, such as co-
morbidities or effect of immunosuppressive treatment.
Conclusion
In conclusion, this study suggests that smoking is an in-
dependent predictor for false negative and indeterminate
IGRA results in patients with active TB. This study adds
further information on the limitations of IGRA, which
may help us to interpret indeterminate results, explain
false negative results, and in the end led to rational clin-
ical use of the IGRAs.
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